Limitations of MS Clinical Trials
The conduct of therapeutic trials in MS is notoriously complex. Investigators are hampered especially by inaccurate diagnosis, unpredictable progression and unreliable indices for monitoring disease activity.
The rigorous diagnostic criteria proposed by Schumacher et al. (1965) are difficult to realize, particularly in patients only mildly afflicted with MS. Recent refinements in imaging, evoked response and electrophoresis technologies have been applied in broader diagnostic guidelines (Poser et al., 1983) .
The major objective of any clinical therapeutic trial must be to separate any effect of the proposed agent from the natural history of the disease. Those patients with recent evidence of disease progression have the best prospects for spontaneous remission, but also are those most likely to be entered into a clinical trial. Studies examining the influence of therapeutic agents on relapse rates must consider that relapse frequency declines with disease duration (McAlpine, 1972) . Other factors to be considered in predicting outcome also have been examined: Duration of disease, development of a progressive course, age at onset, early cerebral involvement and the total number of relapses in the first two years vary directly with disease outcome (Noseworthy et al., 1983) . The rate of progression of the disease eventually may prove to be the most important predictive variable early in the illness.
Investigators evaluating new therapeutic agents also should recall the very large placebo response (69%) in the large cooperative study of ACTH in MS (Rose et al., 1970) .
Any scheme designed to monitor disease activity by clinical assessment is inherently flawed by the well-recognized occurrence of extensive disease activity lacking clinical expression. Autopsy studies reveal widespread CNS demyelination even in patients known to have been asymptomatic through their lives (Georgi, 1961 ; Castaigne etal., 1981; Gilbert and Sadler, 1983; Phadkeet al., 1983) and monosymptomatic relapses may be associated with multifocal lesions on enhanced CT-scans (Ebers et al., 1983) . Furthermore, persisting sclerotic lesions will mask the appearance of, new lesions involving the same CNS tracts. Finally, apparent clinical variations may not be reflecting disease changes at all but merely other independent variables introduced by changes in body temperature, intercurrent illness, emotional change and other poorly understood factors.
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Since variations may occur independently of disease activity per se, investigators must avoid excessively fine scales in their attempts to measure them. Scales which rely heavily upon patient performance at the time of assessment (e.g. ambulation index -the ability to perform a motor task in a given period of time) may be particularly subject to these daily variations. Recognizing certain limitations, we favor the use of a combination of the recently proposed Expanded Disability Status Scale (EDSS) and the functional systems assessment of Kurtzke (1983) .
While contemporary trials are limited by practical factors to utilization of these clinical indices, advances have been made toward more reliable measures of disease activity. A radioimmunoassay for the measurement of material cross-reactive with basic protein fragments 43-88 detects approximately 70% of recent (less than two weeks) clinical relapses and is appropriately nonreactive in patients with no evidence of disease activity (Whitaker et al., 1980) . However, this technique is limited by the requirement for serial lumbar punctures.
Evoked potential recordings will detect some asymptomatic lesions but may be time-consuming and costly. The number of evoked potential abnormalities increases with disease duration. Sequential use of these electrophysiological studies should provide an additional objective measure of disease activity.
Experience with high volume, delayed CT-scanning has shown that 12.5% of patients showing no clinical evidence of active disease still have enhancing abnormalities suggestive of ongoing demyelination (Ebers et al., 1983) . NMR imaging (NMRi) is a sensitive technique for determining white matter abnormalities in patients with longstanding MS (Young et al., 1981; Lukes et al., 1983) . NMRi may be particularly useful for detecting asymptomatic abnormalities in patients with chronic myelopathy and in patients with early MS (Noseworthy et al., 1984) . Sequential studies suggest that NMRi may be useful to monitor the evolution of demyelination, since abnormal Ti and T 2 relaxation times may recover with time in some patients (Noseworthy et al., 1984) . It remains to be seen whether the age and activity of MS plaques can be characterized by quantitative NMR studies. Nevertheless, there is little doubt that this noninvasive technique will be useful for quantitating the extent of CNS involvement.
These and other problems in conducting clinical trials in MS were recognized and clearly outlined in the Schumacher report (1965) . Guidelines for the design of clinical therapeutic studies in MS have been established (Brown et al., 1979) and were the subject of a recent international conference (Herndon and Murray, 1983) .
Clinical Trial Experience
Tables 1 to 5 summarize the results of MS therapeutic trials performed since 1971. Pertinent previous studies included the ACTH cooperative trial alluded to above (Rose et al., 1970) and Most of the studies were not blinded. Admittedly, certain treatment modalities such as cyclophosphamide or plasmapheresis may limit or preclude patient blinding. However, even though blinding of the evaluator may be equally difficult, this should be attempted. Furthermore, even when proper randomization was accomplished, stratification techniques were generally ignored. As a consequence, important differences occurred in the treatment and control groups in terms of age of onset and age of entry dramatic responses were seen in the third group in which sixteen of twenty patients were reported to be stabilized or improved at one year. Unfortunately, eleven of these sixteen responders again developed progressive disease in the second or third year of follow-up. Critics have noted that the study was not blinded, that it lacked an untreated control group, that the follow-up was insufficient, and that the psychological "placebo" effect of the alopecia produced by the cyclophosphamide was not considered (Fishbeck, 1983). Furthermore, most or all of the patients in the study presumably had been previously treated unsuccessfully with ACTH or corticosteroids and therefore patients randomized to receive ACTH alone were aware that they were receiving an agent which failed to benefit them in the past. This may have influenced their treatment expectations and may have magnified the difference in outcome between this control group and patients receiving the "active" agent (cyclophosphamide ± plasmapheresis). Finally, since moderately disabled patients may spontaneously vary by more than a single point over brief intervals on the ambulation index, a change of this magnitude may not necessarily reflect a change in the disease (Miller, 1983) . Even given those qualifications, this study provides some corroborative evidence for earlier reports ( penicillamine, orfrom human immunoglobulin. The controversial results of the study of intrathecal interferon (IFN) by Jacobs et al. (1982) await confirmation of the sixteen further IFN trials currently in progress. Fisher et al. (1980) reported that 5/17 chronic MS patients were improved twelve months following a series of hyperbaric oxygen (HBO) treatments but the disability status score (DSS) changes were not mentioned. The overall DSS change for the treatment group at one year was rather modest (0.59 ± 1.06), the p value of <.006 notwithstanding. A further eight clinical trials are under way to assess the efficacy of HBO. A number of trials are currently in progress to evaluate the effect of cyclosporin A on MS. A fungal metabolite with low myelocy toxicity, cyclosporin A is a potent immunosuppressive with action against proliferating T cells and, to a lesser degree, against B cells. As such, it has major immunosuppressive effects on delayed-type hypersensitivity, cell mediated cytolysis and graft versus host responses and has predictably had a major impact in the field of organ transplantation (White, 1982) . Its possible efficacy in patients with posterior uveitis (Nussenblatt et al., 1983) and in newly-diagnosed juvenile diabetes mellitus (Stiller et al., 1983) and its ability to prevent or attenuate EAE suggests that cyclosporin A may have some effect in modulating a secondary immune response presumably operative in MS. Furthermore, it is possible that future generations of cyclosporin will prove to be more useful and less toxic.
Thus, existing evidence justifies a degree of optimism. Finding that immunosuppressives may be beneficial in some MS patients suggests that this disease is immunologically-mediated. Certainly further carefully-designed, randomized studies are needed and a number of these are in progress including trials evaluating interferon (sixteen trials), HBO (eight), azathioprine (eight), lymphocytapheresis (eight), cyclophosphamide (seven), cyclosporin A (three), plasma exchange (three), total lymphoid irradiation (three), protease inhibitors, transfer factor, staphyloccal phage lysate and monoclonal antibody versus DR2. Future trials should adhere to the guidelines of the Brown Committee (1979) , should attempt to incorporate the markers of disease activity reviewed above and should implement stratification techniques at the time of randomization. The authors are currently developing a large scale, Canadian multicenter placebo-controlled trial to assess and compare the efficacy of the most promising current immunosuppressive protocols in progressive MS following these guidelines.
Potential Risks of Immunosuppressive Therapy
The potential hazards, both immediate and long term, inherent in nonspecific immunosuppression must be carefully considered before administration, particularly to those patients with early disease. Because of the risks, and pending more definitive results, immunosuppression should be restricted to those patients identified as having a poor prognosis. A major concern has been the de novo occurrence of malignancy in immunosuppressed patients. This problem has been particularly well defined in recipients of human allografts (a group of patients which does differ in several important ways from MS patients). Between two and eleven percent of immunosuppressed renal allograft recipients will develop a tumor (Penn, 1979) . Of 3000 patients treated with cyclosporin A to date, 0.5% have developed a lymphoma but experience with this drug is early and the relationship to drug dosage, duration of treatment and association with other immunosuppressives is not clear (Penn, 1982; EditorialLancet, 1983 ).
There are further reasons for caution. Cyclophosphamide, and to a lesser extent other immunosuppressives, inactivates suppressor T cells (Ts) precursors and experimentally may lead to loss of immunological tolerance (Polak et al., 1974) . Mice made resistant to EAE by the generation of T s cells again become susceptible to this disease following pretreatment with low dose cyclophosphamide (Lando et al., 1979) . If active suppressor mechanisms are responsible for remission of MS, it remains possible that elimination of rapidly-dividing Ts precursors by cyclophosphamide could lead to immune enhancement with acceleration of immunologically mediated CNS injury. One could argue therefore that immunosuppressives should be reserved for patients with active disease in whom there is already evidence of disturbed immune regulation.
Future Considerations
It is unlikely that the currently available agents will provide long-term definitive treatment in this disease. Clearly more disease-specific agents will emerge as new immunosuppressives are developed and as more is understood of the etiology and pathogenesis of MS. If, for example, a restricted number of MS-initiating antigens could be identified, it might then be possible to suppress the disordered immune response in an antigen-specific fashion. Conceivably one could induce specific tolerance with in-vivo administration of these purified antigens. In this vein, early attempts to induce antigen-specific tolerance with myelin basic protein have been disappointing (Campbell et al., 1973; Gonsetteetal., 1977; Romine and Salk, 1983) . However, the results of a preliminary study with Copolymer I, a synthetic polypeptide immunologically cross-reactive with myelin basic protein and capable of suppressing EAE, have encouraged investigators to proceed with a full scale clinical trial (Bornstein etal., 1982) .
Another approach could take advantage of the exquisite specificity of the immune response. Unique structural determinants, termed idiotypes, exist on the antigen recognition site of T cells, B cells and antibodies (Oudin and Michel, 1963; Kunkel et al., 1963) . These idiotypes are shared by T and B cells which react against the same antigenic determinants (Binz and Wigzell, 1975) and thus distinguish cells and cell products from others in the immune system. As such, they are immunogenic and the targets of immune regulation. When idiotype-expressing cells proliferate upon exposure to antigen, an anti-idiotypic immune response is generated against these idiotypes. In turn, anti-idiotypic determinants are immunogenic and similarly stimulate an immune response directed against them (antianti-idiot y pic). This chain of events continues until the immune response is down-regulated. There is good evidence that this series of immunological events, initially termed the "network theory of the immune response" by Jerne (1974) , occurs in response to an immune challenge and is an important regulatory mechanism (see review by Rodkey, 1980) . In the future, it may be possible to influence the immune response in MS by modifying idiotype/anti-idiotype interactions in an antigen-specific way (Ebers, 1982) .
Pending substantiation of the numerous promising preliminary reports, only cautious optimism can be offered for the use of immunosuppressive agents in progressive MS. Patients who are clinically stable should be offered only close monitoring and appropriate supportive treatment measures. When disease progression is obvious clinically immunosuppressive measures should be offered only with the full realization of the potential risks and of the limited evidence for their benefit. Optimally, these patients should be treated within the carefully supervised confines of formal clinical trials.
